Diagnostics

Illumina's new partnership with MyOme targets a $200B healthcare savings prize. But can AI-driven genomics overcome the hurdles to deliver resilient returns?

New Phase 2 data shows Elicio's off-the-shelf therapy ELI-002 7P induces "antigen spreading," creating a personalized anti-tumor response.

Biomerica's regulatory win in Egypt is more than a market entry; it's a strategic move to disrupt healthcare with low-cost, rapid diagnostic tools.

A landmark UK study reveals an AI diagnostic tool that predicts heart attacks with stunning accuracy and offers a £25 million lifeline to strained health budgets.

A new rapid saliva test from ImpetusDX promises to revolutionize oral care by linking gum health to systemic disease, but can it overcome market hurdles?

Natera's Signatera test salvaged key insights from a failed clinical trial, creating a new roadmap for personalized breast cancer treatment and logistics.

Advanced AI is reshaping how destinations target travelers. These data-driven strategies offer a powerful playbook for healthcare's patient engagement challenges.

From water quality to workforce dynamics, leaders are tackling unseen threats to build a more resilient, efficient, and safer healthcare system for all.

Behind EVs, AI, and medical breakthroughs lies a hidden process. Discover how ion implantation shapes the chips that power our future and our trust in it.

A French cancer institute is the first in Europe to deploy a new radiotherapy system that promises not just better accuracy, but a more humane patient journey.

CEO Adrian Mendes' major buy-in signals deep confidence as Perimeter Medical AI navigates FDA approval for its game-changing cancer surgery technology.

Century Therapeutics adds M&A and investment heavyweights to its board, a strategic move to navigate the clinical gauntlet with its iPSC-derived diabetes cure.

EPAM and Google Cloud are moving beyond general AI, launching seven production-ready agents designed to solve specific, complex industry problems.

Groundbreaking lymphoma data and a strategic acquisition position Natera to dominate the liquid biopsy market, challenging old standards and creating new value.

Beyond the press release: How two strategic hires signal Plus Therapeutics' aggressive push to commercialize its CNSide platform and capture a $6B market.

A new lab system combines speed, multiplexing, and regulatory trust, promising to accelerate drug development and deepen our biological understanding.

A new alliance explores how inanimate microbes, or postbiotics, could become a novel weapon in oncology, starting with breast cancer research.

For those with severe PTSD and depression, hope is scarce. Biotech firm Compass Pathways is pioneering a psilocybin treatment that could change everything.

Guangdong Jiaying Pharma is leveraging its unique Hakka heritage to enter the global market. But can ancient wisdom navigate modern regulatory and corporate hurdles?

When a 'living drug' for cancer fails, hope fades. A new biologic aims to repaint the target, giving patients' own immune cells a second chance to win.